Bacterium Immune Response Marketing 
Pharmaceutical Technology
OCTOBER 28, 2022
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.
pharmaphorum
DECEMBER 4, 2020
Under the agreement Valneva could receive up to $308 million in cash payments, after Pfizer paid $130 million up front for marketing rights to the vaccine if it succeeds in the clinic. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JULY 28, 2021
The companies are set to go head-to-head in a high-stakes market battle involving billions of dollars — a battle Pfizer has been winning for over a decade now. Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20.
pharmaphorum
JULY 14, 2021
The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.
pharmaphorum
MAY 31, 2022
billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot. GlaxoSmithKline has agreed a $3.3
XTalks
NOVEMBER 10, 2020
Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. Adjuvants are used to help stimulate stronger vaccine immune responses. These are very promising results. Plant-Based Vaccine Technology.
Expert insights. Personalized for you.
162 
Let's personalize your content